Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenvatinib + sintilimab + oxaliplatin + 5-fluorouracil + leucovorin
- Development stage
- Unknown
- Lead developer
- Sun Yat-sen University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy regimen consists of the multi-kinase inhibitor lenvatinib, the PD-1 inhibitor sintilimab, and the FOLFOX chemotherapy backbone (oxaliplatin, 5-fluorouracil, and leucovorin). It is primarily being investigated as a first-line treatment for patients with metastatic intrahepatic cholangiocarcinoma (ICC). Lenvatinib targets multiple receptor tyrosine kinases involved in angiogenesis and tumor progression, including VEGFR1-3, FGFR1-4, PDGFRα, KIT, and RET. Sintilimab is a monoclonal antibody that enhances the anti-tumor immune response by blocking the programmed cell death protein 1 (PD-1) receptor. The FOLFOX component provides cytotoxic activity through oxaliplatin-induced DNA damage and 5-fluorouracil-mediated inhibition of thymidylate synthase, with leucovorin acting as a biochemical modulator to enhance the efficacy of 5-fluorouracil.
- Brand names
- LenvimaTyvyt
- Other names
- Lenvatinib + Sintilimab + FOLFOXLenvatinib + Sintilimab + Oxaliplatin + 5-fluorouracil + LeucovorinSystemic Chemotherapy-Sun Yat-sen University-intrahepatic cholangiocarcinoma
02
Targets
PDGFRA (Platelet-derived growth factor receptor alpha)TS (Thymidylate synthase)PDCD1 (Programmed cell death protein 1 receptor)DNAVEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on lenvatinib + sintilimab + oxaliplatin + 5-fluorouracil + leucovorin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenvatinib + sintilimab + oxaliplatin + 5-fluorouracil + leucovorin.